BMS Jumps Ahead With LAG-3 Melanoma Data

Early Data Suggest Potential For New IO/IO Pairing

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

LAG-3 antibody shows improved PFS when combined with Opdivo in metastatic or inoperable melanoma. Bristol Myers Squibb still awaits overall survival data but could have its second dual checkpoint inhibitor pairing.

Small white flowers on a toned on gentle soft blue and pink background outdoors close-up macro
Early spring brings BMS new potential in immuno-oncology

Bristol Myers Squibb Company reported the first successful Phase III data investigating a LAG-3 antibody in cancer on 25 March, and positive findings in combination with Opdivo (nivolumab) could set the stage for a new combination of checkpoint inhibitors. Though the data are early, the LAG-3 candidate used with the PD-1 inhibitor met the primary endpoint of progression-free survival in patients with previously untreated metastatic or unresectable melanoma.

In the 714-patient, Phase II/III RELATIVITY-047 study, the combination of Opdivo and relatlimab showed a PFS benefit compared to Opdivo...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D